Screen%20Shot%202020-04-01%20at%2010.43_

Ivan Gergel, MD, MBA

Chief Medical Officer & Managing Partner

Dr. Ivan Gergel joined New Rhein as a Managing Partner and CMO in 2017. Ivan is a medical doctor and experienced global pharmaceutical R&D executive whose successes to date include 14 drug approvals. Ivan has held senior leadership positions in several U.S. companies and overseen teams in the development, approval, and commercialization of numerous new medicines. Prior to joining New Rhein, from 2014 to 2017 Ivan was CMO and Head of Drug Development for Nektar Therapeutics, Inc. From 2008 to 2014, Ivan served as Executive VP and Chief Scientific Officer of Endo Health Solutions. Ivan held various roles at Forest Laboratories, Inc. from 1998 to 2008, including Senior VP of R&D and President of the Forest Research Institute. From 1989 to 1998, he worked for SmithKline Beecham in the UK and the U.S. Ivan received his MD from the Royal Free Medical School, University of London, and his MBA from the Wharton School of the University of Pennsylvania. Ivan is a member of the Royal College of Psychiatrists and a fellow of the Faculty of Pharmaceutical Medicine of the UK College of Physicians. He presently serves on the board of Fund 18 portfolio company Neuraptive Therapeutics, Inc., and Butterfly Medical Ltd. Ivan was the former board director of Neurotrope Inc. He has served on the boards of Corium International Inc., Realm Therapeutics, PA BIO,  and of the PhRMA Foundation. Ivan served as a member of the Science and Regulatory Committee of PhRMA. He lives with his wife Ann in Malvern, Pennsylvania.  They have three sons who also live close to them.  Ivan plays tennis and misses playing cricket.